The microbial effect of inhaled steroids in severe COPD patients with associated bronchiectasis
The aim of the study is to investigate whether inhaled steroids along with other types of inhaler, that open the airways, can affect the amount and type of bacteria in the airways. This will be assessed over 1 year in patients with GOLD Stage D COPD and a co-diagnosis of bronchiectasis.
Chief Investigator (UK): Dr Gourab Choudhury
Number and location of participating sites (by region/ country): 3 UK Sites
EudraCT number: 2022-000524-38
ISRCTN number: 15449782
Funder: Glaxo SmithKline
Start and End date of grant award: 01 September 2021 to 29 February 2024
Start and End date of recruitment: May 2022 to January 2023
Current status: In set up
UK GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with UK GDPR, please read this document.
CI: Dr Gourab Choudhury, Royal Infirmary of Edinburgh, Little France, Edinburgh, EH16 4TJ email: Gourab.Choudhury@nhslothian.scot.nhs.uk
Trial Management Team: Lorna Dewar – firstname.lastname@example.org
Research Nurse: Amy McLaren – email@example.com
ECTU Involvement: Trial Management (UK only)